<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Schistosomiasis: Treatment and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Schistosomiasis: Treatment and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Schistosomiasis: Treatment and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Soentjens, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joannes Clerinx, MD, DTM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H13464824">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Schistosomiasis is a disease caused by infection with parasitic blood flukes. The three major species are
         <em>
          Schistosoma mansoni
         </em>
         (Africa and South America),
         <em>
          Schistosoma japonicum
         </em>
         (East Asia), and
         <em>
          Schistosoma haematobium
         </em>
         (Africa and the Middle East). The four minor species are
         <em>
          Schistosoma mekongi
         </em>
         (Laos, Cambodia),
         <em>
          Schistosoma malayi
         </em>
         (Peninsular Malaysia),
         <em>
          Schistosoma intercalatum
         </em>
         , and
         <em>
          Schistosoma guineensis
         </em>
         (West and Central Africa).
        </p>
        <p>
         The treatment and prevention of schistosomiasis will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of schistosomiasis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">
          "Schistosomiasis: Epidemiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5682.html" rel="external">
          "Schistosomiasis: Diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13464830">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of schistosomiasis serves three purposes: reversing acute or early chronic disease, preventing complications associated with chronic infection, and preventing neuroschistosomiasis. The goal of treatment is reduction of egg production via reduction of worm load; this reduces morbidity and mortality even in the absence of complete worm eradication [
         <a href="#rid1">
          1
         </a>
         ]. In endemic areas, repeated treatment is essential for schistosomiasis elimination [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Benefits of treatment include reversal of hydronephrosis and regression of periportal fibrosis in its early stage [
         <a href="#rid3">
          3
         </a>
         ]. However, anthelmintic treatment has little effect on reversing late-stage fibrosis of the hepatic or urinary tract or reversing secondary complications such as portal hypertension with esophageal varices or cor pulmonale.
        </p>
        <p class="headingAnchor" id="H7370613">
         <span class="h2">
          Clinical approach
         </span>
        </p>
        <p class="headingAnchor" id="H5762846">
         <span class="h3">
          Acute infection
         </span>
        </p>
        <p class="headingAnchor" id="H5763226">
         <span class="h4">
          Swimmer's itch
         </span>
         <span class="headingEndMark">
          —
         </span>
         Swimmer's itch is usually caused by repeated exposure to nonhuman schistosome species; humans are not suitable hosts, so the organism dies while in the skin. The rash typically clears within a few days; treatment consists of symptomatic management for pruritus. (See
         <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">
          "Pruritus: Therapies for localized pruritus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5762942">
         <span class="h4">
          Acute schistosomiasis syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute schistosomiasis syndrome (also known as Katayama fever) is a systemic hypersensitivity reaction to schistosome antigens and circulating immune complexes that occurs three to eight weeks after infection; clinical manifestations are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">
          "Schistosomiasis: Epidemiology and clinical manifestations", section on 'Acute schistosomiasis syndrome'
         </a>
         .)
        </p>
        <p>
         Our approach to management of acute schistosomiasis syndrome is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial management consists of reduction of inflammation with corticosteroids [
         <a href="#rid4">
          4,5
         </a>
         ]. The optimal dose and duration of corticosteroids are uncertain; in general, we treat with
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (1 mg/kg per day) until symptoms subside and for 48 hours thereafter (typically 3 to 10 days) [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subsequently, we favor administration of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         (40 mg/kg once) 8 to 12 weeks after infection, together with
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (1 mg/kg per day for 1 to 3 days), and only after the initial acute symptoms have been fully suppressed with corticosteroids alone. Failure to do so may cause symptoms to (re)appear [
         <a href="#rid8">
          8-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         is administered to prevent chronic infection and serious complications such as early neuroschistosomiasis [
         <a href="#rid13">
          13,14
         </a>
         ]. Data on optimal timing of treatment are limited. In general, praziquantel is effective only when given at least 4 to 8 weeks following exposure (ie, once infection is well established and the worms have fully matured) [
         <a href="#rid8">
          8
         </a>
         ]. In one animal model, praziquantel had no activity in the first 21 days after infection, low activity at day 28, and 100 percent activity at day 52 [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Corticosteroids are given with initial treatment because administration of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         within 12 weeks after infection may be associated with aggravation of symptoms [
         <a href="#rid4">
          4,9,16
         </a>
         ]. Corticosteroids reduce plasma levels of praziquantel; however, data are limited regarding whether the praziquantel dosing warrants adjustment in the setting of corticosteroids [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Finally, we administer
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         (40 mg/kg once) once again four to six weeks later, but not earlier than three months after infection (without corticosteroids), to eliminate the remaining schistosomes that matured in the interim period since the previous treatment [
         <a href="#rid10">
          10,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5762853">
         <span class="h3">
          Chronic infection
         </span>
        </p>
        <p class="headingAnchor" id="H2484781">
         <span class="h4">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among individuals in endemic areas, the goal of treatment is to reduce parasite burden and morbidity (given that reinfection is unavoidable). Among individuals outside of endemic areas, the goal of treatment is definitive cure.
        </p>
        <p>
         Patients with known recent exposure should have treatment deferred until diagnostic serology and/or microscopy can be performed (generally positive 6 to 12 weeks after exposure) and symptoms of acute disease (if present) have subsided. (See
         <a class="local">
          'Acute schistosomiasis syndrome'
         </a>
         above.)
        </p>
        <p>
         In endemic areas, a single dose of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         is curative in 20 to 100 percent of cases [
         <a href="#rid18">
          18
         </a>
         ]; among individuals who are not cured, praziquantel reduces the parasite burden by 30 to 90 percent depending on the diagnostic methods used [
         <a href="#rid18">
          18-23
         </a>
         ]. Retreatment of patients with residual infection only marginally increases cure rates [
         <a href="#rid23">
          23-26
         </a>
         ].
        </p>
        <p>
         Among travelers and expatriates, whose parasite burden is usually low, a single dose of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         is generally sufficient to reduce the worm burden to negligible levels [
         <a href="#rid12">
          12,27
         </a>
         ]. Some use higher doses for and/or prolonged duration of treatment; however, data to support this approach are limited [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Dosing of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         for infection due to
         <em>
          S. haematobium
         </em>
         ,
         <em>
          S. mansoni,
         </em>
         or
         <em>
          S. intercalatum
         </em>
         consists of 40 mg/kg in one or two (divided) doses [
         <a href="#rid26">
          26
         </a>
         ]. Dosing for infection due to
         <em>
          S. japonicum
         </em>
         or
         <em>
          S. mekongi
         </em>
         consists of 60 mg/kg in two divided doses [
         <a href="#rid19">
          19,20,27
         </a>
         ]. A repeat dose of praziquantel given two to six weeks after the initial dose may improve cure rate or further reduce the intensity of
         <em>
          S. mansoni
         </em>
         infection, although this is not a standard practice [
         <a href="#rid28">
          28
         </a>
         ]. This may apply to other schistosome species as well.
        </p>
        <p>
         Follow-up after treatment includes monitoring of clinical manifestations, eosinophil count (in patients with eosinophilia), microscopy evaluation for eggs in stool or urine. Neither serology nor serum polymerase chain reaction tests are suitable as a useful monitoring tool, as both remain positive for prolonged periods following treatment [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Eosinophil levels may increase shortly after treatment and subsequently decrease over several weeks [
         <a href="#rid29">
          29
         </a>
         ]. Persistent eosinophilia for more than three months after treatment may reflect insufficient reduction of parasite burden and/or may indicate the presence of an additional helminth infection.
        </p>
        <p>
         In endemic areas, follow-up microscopy of stool or urine for assessment of parasite load reduction and cure should be performed no sooner than six weeks following treatment. In nonendemic areas, follow-up microscopy may be performed three to six months after treatment, since there is no risk of intercurrent reinfection [
         <a href="#rid30">
          30
         </a>
         ]. Egg excretion may continue for a few weeks after treatment and differentiating viable from nonviable eggs may be difficult. In addition, treatment may cause temporary cessation of egg production from adult worms that are not killed.
        </p>
        <p>
         Presence of viable eggs 6 to 12 weeks after initial therapy warrants repeat treatment with
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         . The same dose of praziquantel (40 mg/kg for infection due to
         <em>
          S. haematobium
         </em>
         ,
         <em>
          S. mansoni,
         </em>
         or
         <em>
          S. intercalatum
         </em>
         ; 60 mg/kg for infection due to
         <em>
          S. japonicum
         </em>
         or
         <em>
          S. mekongi
         </em>
         ) may be administered [
         <a href="#rid27">
          27
         </a>
         ]. There does not appear to be an advantage to increasing the dose in retreatment [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         In populations with a high parasite burden, radiographic imaging (abdominal ultrasound or magnetic resonance imaging) is essential to document long-term reversal of urinary tract lesions and of periportal liver disease following repeated mass treatment [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Detection of circulating anodic antigen in serum and urine offers a promising development in monitoring treatment efficacy in
         <em>
          S. haematobium complex
         </em>
         infection, but is not yet routinely available [
         <a href="#rid34">
          34
         </a>
         ]. For
         <em>
          S. mansoni,
         </em>
         results of a point-of care circulating cathodic antigen urine test lacked sensitivity and specificity in low-endemic areas [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Issues related to population deworming are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91857.html" rel="external">
          "Mass drug administration for control of parasitic infections", section on 'Clinical approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5763365">
         <span class="h4">
          Genitourinary schistosomiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary schistosomiasis can cause genital lesions during childhood. Repeated treatment with
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         may reverse such lesions, more so in younger patients [
         <a href="#rid36">
          36
         </a>
         ]. Genital schistosomiasis increases vaginal mucosal fragility and bleeding in adult women and has been associated with increased risk of HIV acquisition in several studies [
         <a href="#rid37">
          37
         </a>
         ]. While genital lesions in adults are chronic, it is assumed that early and repeated treatment with praziquantel could substantially reduce local tissue inflammation and HIV incidence [
         <a href="#rid38">
          38
         </a>
         ]. Genital schistosomiasis has been associated with female infertility [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Issues related to schistosomiasis and glomerular disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3057.html" rel="external">
          "Schistosomiasis and glomerular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H332980396">
         <span class="h4">
          Hepatosplenic schistosomiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatosplenic schistosomiasis associated with intestinal schistosomiasis can cause severe portal hypertension and gastrointestinal bleeding. Repeated mass treatment with
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         has substantially reduced both splenomegaly and hepatic fibrosis especially in younger patients [
         <a href="#rid36">
          36
         </a>
         ]. In adult patients with established hepatic fibrosis with portal hypertension, variceal bleeding is the most common complication. Treatment options include surgical portosystemic shunt or esophagogastric devascularization with splenectomy, and medical treatment with beta-blockers [
         <a href="#rid40">
          40
         </a>
         ]; the optimal approach is uncertain [
         <a href="#rid41">
          41-44
         </a>
         ]. In one case series including 45 patients with hepatosplenic schistosomiasis who underwent splenectomy, reduction in portal hypertension and improvement in coagulation factors and liver function tests were observed [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Hepatosplenic schistosomiasis is associated with glomerular dysfunction. Patients with hepatosplenic schistosomiasis living in endemic regions warrant annual screening for glomerular disease and renal dysfunction via measurement of serum creatinine and urine dipstick testing (to evaluate for presence of proteinuria and/or hematuria) [
         <a href="#rid45">
          45
         </a>
         ]. If an abnormal urine dipstick result is observed, the urine sediment should be examined, and proteinuria should be quantified with a urine protein-to-creatinine ratio.
        </p>
        <p>
         Issues related to schistosomiasis and glomerular disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3057.html" rel="external">
          "Schistosomiasis and glomerular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2484977">
         <span class="h4">
          Neuroschistosomiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuroschistosomiasis develops as a result of embolization of adult worms to the spinal cord or cerebral microcirculation, with subsequent release of eggs leading to an intense inflammatory reaction with local tissue destruction and scarring. It can cause cerebral disease or myelopathy; the latter is more common. Clinical manifestations are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">
          "Schistosomiasis: Epidemiology and clinical manifestations", section on 'Neuroschistosomiasis'
         </a>
         .)
        </p>
        <p>
         Prompt corticosteroid treatment (
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 to 2 mg/kg per day) is essential to limit irreversible tissue damage that occurs as a result of the intense inflammatory response mainly towards the embolized eggs [
         <a href="#rid46">
          46-48
         </a>
         ]. If the diagnosis of neuroschistosomiasis is suspected but not proven, corticosteroid therapy should be administered, nonetheless. The approach to diagnosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5682.html" rel="external">
          "Schistosomiasis: Diagnosis", section on 'Neuroschistosomiasis'
         </a>
         .)
        </p>
        <p>
         The duration of corticosteroid therapy is uncertain; in general, treatment should be continued for several months but could be tapered off gradually, tailored to individual circumstances. Premature interruption or tapering off steroid dosage too quickly may result in clinical relapse [
         <a href="#rid49">
          49
         </a>
         ]. In one study including 16 patients with myeloradiculopathy due to neuroschistosomiasis, the best clinical outcome was achieved among patients who received steroid treatment for at least two months [
         <a href="#rid50">
          50
         </a>
         ]. In the setting of prolonged corticosteroid use, concomitant infection with
         <em>
          Strongyloides
         </em>
         should be excluded or treated to prevent the syndrome of strongyloidiasis hyperinfection. (See
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         (40 mg/kg single dose) can provoke an inflammatory response with paradoxical worsening of neurologic symptoms and should therefore be administered a few days after initiation of corticosteroid treatment [
         <a href="#rid51">
          51-53
         </a>
         ]. Praziquantel may be sufficient for elimination of adult worms and halting egg production, but it does not inactivate eggs embedded at ectopic sites, hence the need for prolonged corticosteroid treatment [
         <a href="#rid54">
          54
         </a>
         ]. In neuroschistosomiasis, repeated doses of praziquantel (40 to 60 mg/kg per day for 3 days) are often given, but the added benefit is uncertain [
         <a href="#rid49">
          49
         </a>
         ]. In the setting of associated seizures, anticonvulsant therapy should be administered. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults", section on 'Antiseizure medication therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2484726">
         <span class="h2">
          Anthelminthic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H13464848">
         <span class="h3">
          Praziquantel
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         alters the tegument structure of adult worms and increases calcium ion permeability. Calcium ions accumulate in the cytosol, leading to muscular contractions and subsequent paralysis. Damage to the tegument membrane also induces a host immune response to parasite antigens [
         <a href="#rid55">
          55
         </a>
         ]. Therefore, the efficacy of praziquantel depends on both the parasite burden of infection and the host immune defense [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         is readily absorbed when taken orally with food and has a short plasma half-life [
         <a href="#rid17">
          17
         </a>
         ]. Adverse effects of praziquantel occur in approximately one-third of patients and are generally mild. They include dizziness, headache, vomiting, abdominal pain, diarrhea, and pruritus. These symptoms may be attributable to the drug itself and/or to the host immune response to dying parasites. Therefore, adverse effects may be observed more frequently among patients with high parasite burden [
         <a href="#rid57">
          57
         </a>
         ]. Paradoxical hypersensitivity reactions following treatment with praziquantel may be observed among travelers with acute infection and/or in the setting of early chronic schistosomiasis [
         <a href="#rid9">
          9,11,57
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         may be used in pregnancy [
         <a href="#rid58">
          58-62
         </a>
         ]. One trial including 370 pregnant women randomized to receive praziquantel or placebo noted no significant differences in safety outcomes including abortion, fetal death in utero, and congenital abnormalities [
         <a href="#rid62">
          62
         </a>
         ]. Praziquantel is excreted in human breast milk, although no adverse effects during lactation have been reported; most favor discontinuation of breastfeeding at the time of treatment and for 72 hours thereafter or delaying treatment until after breastfeeding.
        </p>
        <p class="headingAnchor" id="H7366350">
         <span class="h3">
          Drug resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         True resistance to
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         remains exceptional, despite its extensive use in endemic regions for many years [
         <a href="#rid18">
          18
         </a>
         ]. Praziquantel probably acts on multiple pharmacologically relevant targets, with a combined detrimental effect on the parasite [
         <a href="#rid63">
          63
         </a>
         ]. Schistosome species with reduced sensitivity to praziquantel in vivo and in vitro have been described [
         <a href="#rid57">
          57,64-69
         </a>
         ]; it is unclear if these observations represent resistance or reinfection. In addition, the distinction between worm burden reduction and failure to eradicate infection in these reports is not always clear.
        </p>
        <p>
         In a region of
         <em>
          S. mansoni
         </em>
         transmission in Senegal,
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         was curative among only 35 percent of individuals; this may be related to high parasite burden and intense transmission with rapid reinfection [
         <a href="#rid65">
          65,66
         </a>
         ]. Another report noted that
         <em>
          S. mansoni
         </em>
         parasites demonstrated reduced killing upon exposure to praziquantel in vitro [
         <a href="#rid69">
          69
         </a>
         ]. Therapeutic failure has also been reported in travelers [
         <a href="#rid67">
          67,68,70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7366108">
         <span class="h3">
          Alternative therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxamniquine is occasionally used for refractory
         <em>
          S. mansoni
         </em>
         infection. It is contraindicated in pregnancy and is not as effective as
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         [
         <a href="#rid72">
          72,73
         </a>
         ]. Research is ongoing to develop derivatives of oxamniquine as a broad-spectrum anti-schistosome treatment [
         <a href="#rid74">
          74
         </a>
         ]. Artemisinin derivatives act on the glucose metabolism of immature schistosomes [
         <a href="#rid75">
          75
         </a>
         ] and could be of use in very early infection [
         <a href="#rid8">
          8
         </a>
         ]. The concentration of praziquantel may be increased by coadministration of dihydroartemisinin-piperaquine [
         <a href="#rid76">
          76
         </a>
         ], and a trial has demonstrated that combination therapy with these drugs is more effective than praziquantel alone [
         <a href="#rid77">
          77
         </a>
         ].
         <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">
          Mefloquine
         </a>
         has limited action on mature worms. The addition of mefloquine or
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         to praziquantel is of limited value [
         <a href="#rid78">
          78,79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13464908">
         <span class="h1">
          CONTROL AND PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Schistosomiasis control strategies for endemic areas include periodic mass treatment, water sanitation programs, and vaccine development. In areas with intense transmission, the principal objectives of control programs include infection control and reduction of schistosome morbidity. The association between parasite burden and morbidity is species specific; it is much more pronounced in
         <em>
          S. haematobium
         </em>
         infection than in
         <em>
          S. mansoni
         </em>
         infection [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         The main control activity advocated by the World Health Organization (WHO) consists of periodic mass drug administration, which reduces the adult worm burden and ensuing morbidity; this approach also reduces the intensity of reinfection over time [
         <a href="#rid81">
          81-86
         </a>
         ]. Periodic mass treatment is particularly beneficial among school age children, who usually carry the highest parasite burden. Repeated treatment accelerates immunologic resistance against reinfection in this age group, significantly reducing morbidity.
        </p>
        <p>
         The approach to mass treatment consists of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         administration (single dose 40 mg/kg orally) to school children and adults (including pregnant women). Most treatment programs are school centered; preschool children are less affected and praziquantel is relatively contraindicated for toddlers &lt;4 years.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         treatment is given on an annual or biannual basis depending on regional species and transmission intensity [
         <a href="#rid59">
          59,60,87
         </a>
         ]. In one study including more than 12,000 children with urinary schistosomiasis in Cote d'Ivoire, the prevalence of
         <em>
          S. haematobium
         </em>
         was lower among those who received biannual treatment rather than annual treatment (0.6 versus 7.5 percent); however, interruption of transmission was not achieved [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
         Annual mass drug administration is appropriate for disease control in most settings. In some settings, multiple rounds of mass
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         administration have been associated with diminished efficacy, particularly in regions with high endemicity levels [
         <a href="#rid89">
          89
         </a>
         ]. However, there is no clear evidence for emergence of praziquantel resistance. In a 2022 treatment guideline, the WHO recommended to treat a larger section of the population more frequently, even in lower schistosome prevalence settings [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         kills adult larvae but does not kill eggs or immature worms that may sustain transmission in between treatment rounds. [
         <a href="#rid8">
          8,9
         </a>
         ]. As an example, in a systematic review of multiyear data from control programs implementing mass praziquantel administration as the key intervention strategy in several countries (Mali, Niger, Burkina Faso, Rwanda, Uganda, Burundi, Tanzania, Malawi, and Yemen), a reduction in prevalence of heavy-intensity
         <em>
          S. mansoni
         </em>
         and
         <em>
          S. haematobium
         </em>
         infection among school-age children to &lt;5 percent was observed in all countries except Niger [
         <a href="#rid91">
          91
         </a>
         ]. Elimination (reduction in prevalence to &lt;1 percent) was achieved in half of the countries, for
         <em>
          S. mansoni
         </em>
         infection only. Sustained control of schistosomiasis requires repeated therapeutic intervention and concerted action to eliminate transmission at the long run. In many settings with high transmission rates, periodic mass drug administration alone may not be sufficient to eradicate schistosomiasis infection; additional measures are needed [
         <a href="#rid92">
          92-94
         </a>
         ]. These include environmental measures targeting the transmission dynamics by (1) interfering with the biology of the intermediate host and (2) reducing the risk of reinfection from water sources. In some regions with less intense or more focal transmission, combining these measures may render eradication feasible. More precise diagnostics may be needed to achieve eradication [
         <a href="#rid23">
          23
         </a>
         ]. These and other measures have facilitated eradication of schistosomiasis in Japan and have been adopted as a national strategy in China [
         <a href="#rid92">
          92,94,95
         </a>
         ].
        </p>
        <p>
         Minimizing contact with fresh water containing infectious cercarial larvae is an important control measure. Interventions include provision of safe water supplies with proper sewage control and community education regarding wearing protective clothing and footwear in the setting of freshwater exposure [
         <a href="#rid96">
          96
         </a>
         ]. Other measures include vigorous toweling of exposed skin and/or applying insect repellent DEET (N,N-diethyl-m-toluamide) following fresh water exposure [
         <a href="#rid97">
          97
         </a>
         ]. Eradication of snail species via molluscicides (eg, niclosamide, copper sulphate) or control of snail breeding sites has been attempted, although such measures difficult to sustain because repopulation can occur rapidly and because of downstream environmental effects [
         <a href="#rid96">
          96,98
         </a>
         ].
        </p>
        <p>
         Vaccination could play a significant role in resistance to infection. Vaccines may alter the outcome of schistosomiasis infection by acting upon the delicate interplay between T helper cell reactions (Th1 and Th2) directed towards schistosome egg antigens embedded in tissues. Vaccines targeting the invasive stage (cercariae, schistosomules) may increase resistance to infection. Several schistosome antigens have been identified as vaccine candidates, and various vaccine platforms have been considered [
         <a href="#rid99">
          99,100
         </a>
         ]. Others have been extensively tested in animal models of zoonotic schistosomiasis (
         <em>
          S. japonicum
         </em>
         ) with variable results. The S. mansoni controlled human infection (CHI-S) model offers an exciting platform to test schistosome vaccine candidates in humans [
         <a href="#rid101">
          101-105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3689087177">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/127188.html" rel="external">
          "Society guideline links: Schistosomiasis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13464920">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of schistosomiasis serves three purposes: reversing acute or early chronic disease, preventing complications associated with chronic infection, and preventing neuroschistosomiasis. The goal of treatment is reduction of egg production via reduction of worm load. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with acute schistosomiasis syndrome, our approach consists of initial management with corticosteroids to reduce inflammation. Thereafter, we suggest administration of
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         8 to 12 weeks after infection (together with
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         ), followed by repeat praziquantel treatment 4 to 6 weeks later (without corticosteroids) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Corticosteroids are given with initial treatment because administration of praziquantel within 12 weeks following infection may be associated with aggravation of symptoms (See
         <a class="local">
          'Acute schistosomiasis syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with chronic infection, we suggest treatment with
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         (single dose) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Dosing of praziquantel for treatment of infection due to
         <em>
          Schistosoma haematobium
         </em>
         ,
         <em>
          Schistosoma mansoni,
         </em>
         or
         <em>
          Schistosoma intercalatum
         </em>
         consists of 40 mg/kg (in one or two divided doses). Praziquantel dosing for treatment of infection due to
         <em>
          Schistosoma japonicum
         </em>
         or
         <em>
          Schistosoma mekongi
         </em>
         consists of 60 mg/kg (in two divided doses). (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follow-up after treatment includes monitoring of clinical manifestations, eosinophilia, and microscopy evaluation for eggs in stool or urine. In endemic areas, follow-up microscopy should be performed no sooner than six weeks following treatment. In nonendemic areas, follow-up microscopy may be performed three to six months after treatment. Persistence of viable eggs after treatment with
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          praziquantel
         </a>
         warrants repeat treatment. (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of neuroschistosomiasis consists of prompt and sustained corticosteroid treatment.
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         should be administered a few days after initiation of corticosteroid treatment; the two therapies should be given concomitantly. (See
         <a class="local">
          'Neuroschistosomiasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schistosomiasis control strategies for endemic areas include mass treatment and water sanitation programs. (See
         <a class="local">
          'Control and prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13464927">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Karin Leder, MD, and Peter Weller, MD, who contributed to an earlier version of this topic.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 2003; 86:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monnier N, Barth-Jaeggi T, Knopp S, Steinmann P. Core components, concepts and strategies for parasitic and vector-borne disease elimination with a focus on schistosomiasis: A landscape analysis. PLoS Negl Trop Dis 2020; 14:e0008837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas AO, Akpom CA, Cockshott WP, Bohrer SP. Reversibility of the urological lesions of schistosomiasis in children after specific therapy. Ann N Y Acad Sci 1969; 160:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauréguiberry S, Paris L, Caumes E. Acute schistosomiasis, a diagnostic and therapeutic challenge. Clin Microbiol Infect 2010; 16:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman PJ, Wilkinson PR, Davidson RN. Acute schistosomiasis (Katayama fever) among British air crew. BMJ 1988; 297:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harries AD, Cook GC. Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy. J Infect 1987; 14:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandière-Pérez L, Ansart S, Paris L, et al. Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers. Am J Trop Med Hyg 2006; 74:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006; 52:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cnops L, Huyse T, Maniewski U, et al. Acute Schistosomiasis With a Schistosoma mattheei × Schistosoma haematobium Hybrid Species in a Cluster of 34 Travelers Infected in South Africa. Clin Infect Dis 2021; 72:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumayr AL, Tschirky B, Warren A, et al. Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis. J Travel Med 2012; 19:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langenberg MCC, Hoogerwerf MA, Koopman JPR, et al. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics. Nat Med 2020; 26:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biber A, Petersil N, Naaman E, et al. Unusual and Severe Complications of Acute Schistosomiasis in Travelers. Open Forum Infect Dis 2022; 9:ofac443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnefond S, Cnops L, Duvignaud A, et al. Early complicated schistosomiasis in a returning traveller: Key contribution of new molecular diagnostic methods. Int J Infect Dis 2019; 79:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Utzinger J, Keiser J, Shuhua X, et al. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003; 47:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauréguiberry S, Paris L, Caumes E. Difficulties in the diagnosis and treatment of acute schistosomiasis. Clin Infect Dis 2009; 48:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987; 37:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukushige M, Chase-Topping M, Woolhouse MEJ, Mutapi F. Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy. PLoS Negl Trop Dis 2021; 15:e0009189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guisse F, Polman K, Stelma FF, et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg 1997; 56:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King CH, Wiper DW 3rd, De Stigter KV, et al. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg 1989; 40:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs 1991; 42:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra PT, Casacuberta-Partal M, van Lieshout L, et al. Limited efficacy of repeated praziquantel treatment in Schistosoma mansoni infections as revealed by highly accurate diagnostics, PCR and UCP-LF CAA (RePST trial). PLoS Negl Trop Dis 2022; 16:e0011008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail MM, Attia MM, el-Badawy AA, et al. Treatment of schistosomiasis with praziquantel among school children. J Egypt Soc Parasitol 1994; 24:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tukahebwa EM, Vennervald BJ, Nuwaha F, et al. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg 2013; 107:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer CV, Zhang F, Sinclair D, Olliaro PL. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2014; :CD000053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Utzinger J, N'Goran EK, N'Dri A, et al. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 2000; 5:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucchetto G, Buonfrate D, Marchese V, et al. High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review. J Travel Med 2019; 26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993; 7:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danso-Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev 2013; :CD000528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olliaro PL, Vaillant MT, Belizario VJ, et al. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 2011; 5:e1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olveda DU, Olveda RM, Lam AK, et al. Utility of Diagnostic Imaging in the Diagnosis and Management of Schistosomiasis. Clin Microbiol 2014; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra PT, van Esbroeck M, de Dood CJ, et al. Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study. Travel Med Infect Dis 2021; 41:102053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clements MN, Corstjens PLAM, Binder S, et al. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi. Parasit Vectors 2018; 11:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis. PLoS Negl Trop Dis 2017; 11:e0005372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbabazi PS, Andan O, Fitzgerald DW, et al. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 2011; 5:e1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ndeffo Mbah ML, Poolman EM, Atkins KE, et al. Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women. PLoS Negl Trop Dis 2013; 7:e2346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjetland EF, Kurewa EN, Mduluza T, et al. The first community-based report on the effect of genital Schistosoma haematobium infection on female fertility. Fertil Steril 2010; 94:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinkala E, Vinikoor M, Zyambo K, et al. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study. Am J Trop Med Hyg 2020; 102:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leite LA, Pimenta Filho AA, Ferreira Rde C, et al. Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni. PLoS One 2015; 10:e0135370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda MA, Ferraz ÁA, Domingues AL, et al. Improvement of schistosomal portal hypertensive colopathy after surgical treatment. Arq Gastroenterol 2013; 50:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ede CJ, Nikolova D, Brand M. Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis. Cochrane Database Syst Rev 2018; 8:CD011717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamarozzi F, Fittipaldo VA, Orth HM, et al. Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature. PLoS Negl Trop Dis 2021; 15:e0009191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neves PDMM, Jorge LB, Cavalcante LB, et al. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes . Clin Nephrol 2020; 93:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari TC, Moreira PR, Cunha AS. Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment. Acta Trop 2008; 108:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peregrino AJ, Puglia PM, Nobrega JP, et al. [Schistosomiasis of the spinal cord: analysis of 80 cases]. Arq Neuropsiquiatr 2002; 60:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler R, Lee C, Keystone JS. The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion. Am J Trop Med Hyg 1999; 61:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Wilton A, Aggarwal D, Jäger HR, et al. Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: A tertiary referral centre experience. PLoS Negl Trop Dis 2021; 15:e0009161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva LC, Maciel PE, Ribas JG, et al. Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study. Clin Infect Dis 2004; 39:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari TC, Moreira PR. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol 2011; 10:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauréguiberry S, Ansart S, Perez L, et al. Acute neuroschistosomiasis: two cases associated with cerebral vasculitis. Am J Trop Med Hyg 2007; 76:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross AG, McManus DP, Farrar J, et al. Neuroschistosomiasis. J Neurol 2012; 259:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watt G, Adapon B, Long GW, et al. Praziquantel in treatment of cerebral schistosomiasis. Lancet 1986; 2:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol 1990; 71:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lieshout L, Stelma FF, Guissé F, et al. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 1999; 61:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelma FF, Talla I, Sow S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995; 53:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savioli L, Crompton DW, Neira M. Use of anthelminthic drugs during pregnancy. Am J Obstet Gynecol 2003; 188:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam I, Elwasila el T, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004; 98:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam I, Elwasila E, Homeida M. Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. Ann Trop Med Parasitol 2005; 99:37.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months. World Health Organization, Geneva 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olveda RM, Acosta LP, Tallo V, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas CM, Timson DJ. The Mechanism of Action of Praziquantel: Six Hypotheses. Curr Top Med Chem 2018; 18:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cioli D. Chemotherapy of schistosomiasis: an update. Parasitol Today 1998; 14:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gryseels B, Stelma F, Talla I, et al. Immuno-epidemiology of Schistosoma mansoni infections in a recently exposed community in Senegal. Mem Inst Oswaldo Cruz 1995; 90:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gryseels B, Mbaye A, De Vlas SJ, et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001; 6:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso D, Muñoz J, Gascón J, et al. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 2006; 74:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva IM, Thiengo R, Conceição MJ, et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz 2005; 100:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999; 60:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herwaldt BL, Tao LF, van Pelt W, et al. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin Infect Dis 1995; 20:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helleberg M, Thybo S. High rate of failure in treatment of imported schistosomiasis. J Travel Med 2010; 17:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008; 14:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol 2014; 195:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzman MA, Rugel AR, Tarpley RS, et al. An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans. PLoS Negl Trop Dis 2020; 14:e0008517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araújo N, Kohn A, Katz N. Activity of the artemether in experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 1991; 86 Suppl 2:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minzi OM, Mnkugwe RH, Ngaimisi E, et al. Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection. Pharmaceuticals (Basel) 2021; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mnkugwe RH, Minzi O, Kinung'hi S, et al. Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. PLoS Negl Trop Dis 2020; 14:e0008619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keiser J, Silué KD, Adiossan LK, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis 2014; 8:e2975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmorshedy H, Tanner M, Bergquist RN, et al. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial. Acta Trop 2016; 158:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegand RE, Secor WE, Fleming FM, et al. Associations between infection intensity categories and morbidity prevalence in school-age children are much stronger for Schistosoma haematobium than for S. mansoni. PLoS Negl Trop Dis 2021; 15:e0009444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutapi F, Maizels R, Fenwick A, Woolhouse M. Human schistosomiasis in the post mass drug administration era. Lancet Infect Dis 2017; 17:e42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koukounari A, Gabrielli AF, Toure S, et al. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 2007; 196:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabatereine NB, Brooker S, Koukounari A, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 2007; 85:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin D, Zhang S, Murakami H, et al. Impact mass chemotherapy with praziquantel on schistosomiasis control in Fanhu village, People's Republic of China. Southeast Asian J Trop Med Public Health 1997; 28:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talaat M, Miller FD. A mass chemotherapy trial of praziquantel on Schistosoma haematobium endemicity in Upper Egypt. Am J Trop Med Hyg 1998; 59:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleland CR, Tukahebwa EM, Fenwick A, Blair L. Mass drug administration with praziquantel reduces the prevalence of Schistosoma mansoni and improves liver morbidity in untreated preschool children. Trans R Soc Trop Med Hyg 2014; 108:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuesch R, Zimmerli L, Stockli R, et al. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005; 12:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouattara M, Bassa FK, Diakité NR, et al. Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial. Clin Infect Dis 2022; 74:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crellen T, Walker M, Lamberton PH, et al. Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration. Clin Infect Dis 2016; 63:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo NC, Bezerra FSM, Colley DG, et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect Dis 2022; 22:e327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deol AK, Fleming FM, Calvo-Urbano B, et al. Schistosomiasis - Assessing Progress toward the 2020 and 2025 Global Goals. N Engl J Med 2019; 381:2519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang LD, Chen HG, Guo JG, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009; 360:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross AG, Olveda RM, Chy D, et al. Can mass drug administration lead to the sustainable control of schistosomiasis? J Infect Dis 2015; 211:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon CA, Kurscheid J, Williams GM, et al. Asian Schistosomiasis: Current Status and Prospects for Control Leading to Elimination. Trop Med Infect Dis 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka H, Tsuji M. From discovery to eradication of schistosomiasis in Japan: 1847-1996. Int J Parasitol 1997; 27:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinmann P, Keiser J, Bos R, et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson F, Doherty JF, Behrens RH. Schistosomiasis prophylaxis in vivo using N,N-diethyl-m-toluamide (DEET). Trans R Soc Trop Med Hyg 2003; 97:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenwick A. Waterborne infectious diseases--could they be consigned to history? Science 2006; 313:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McManus DP, Bergquist R, Cai P, et al. Schistosomiasis-from immunopathology to vaccines. Semin Immunopathol 2020; 42:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molehin AJ, McManus DP, You H. Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects. Int J Mol Sci 2022; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harn DA, Reynolds SR, Chikunguwo S, et al. Synthetic peptide vaccines for schistosomiasis. Pharm Biotechnol 1995; 6:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janse JJ, Langenberg MCC, Kos-Van Oosterhoud J, et al. Establishing the Production of Male Schistosoma mansoni Cercariae for a Controlled Human Infection Model. J Infect Dis 2018; 218:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrifield M, Hotez PJ, Beaumier CM, et al. Advancing a vaccine to prevent human schistosomiasis. Vaccine 2016; 34:2988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tebeje BM, Harvie M, You H, et al. Schistosomiasis vaccines: where do we stand? Parasit Vectors 2016; 9:528.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5705 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12745135" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The impact of chemotherapy on morbidity due to schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33125375" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Core components, concepts and strategies for parasitic and vector-borne disease elimination with a focus on schistosomiasis: A landscape analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5259283" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reversibility of the urological lesions of schistosomiasis in children after specific therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20222897" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute schistosomiasis, a diagnostic and therapeutic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317603" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Katayama syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3143440" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acute schistosomiasis (Katayama fever) among British air crew.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3106506" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687686" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16169593" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Imported Katayama fever: clinical and biological features at presentation and during treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32215659" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute Schistosomiasis With a Schistosoma mattheei×Schistosoma haematobium Hybrid Species in a Cluster of 34 Travelers Infected in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22776392" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute febrile respiratory reaction after praziquantel treatment during asymptomatic late form of acute schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32066978" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36172058" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Unusual and Severe Complications of Acute Schistosomiasis in Travelers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30502485" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Early complicated schistosomiasis in a returning traveller: Key contribution of new molecular diagnostic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12709312" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19292640" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Difficulties in the diagnosis and treatment of acute schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3627459" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Plasma levels of praziquantel decrease when dexamethasone is given simultaneously.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33730095" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9180600" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2499203" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9924961" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1720380" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Schistosomiasis drug therapy and treatment considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36548444" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Limited efficacy of repeated praziquantel treatment in Schistosoma mansoni infections as revealed by highly accurate diagnostics, PCR and UCP-LF CAA (RePST trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7844413" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of schistosomiasis with praziquantel among school children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23596262" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25099517" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Drugs for treating urinary schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11123824" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31309979" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/448186" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8254164" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450530" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Drugs for treating Schistosoma mansoni infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21695161" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25110719" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Utility of Diagnostic Imaging in the Diagnosis and Management of Schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33823289" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29475457" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28212414" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22163056" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Examining the relationship between urogenital schistosomiasis and HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23936578" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20149365" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The first community-based report on the effect of genital Schistosoma haematobium infection on female fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32067625" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26267788" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23903627" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Improvement of schistosomal portal hypertensive colopathy after surgical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073663" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33764979" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32228829" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18499080" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12244399" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : [Schistosomiasis of the spinal cord: analysis of 80 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10432054" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33571228" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: A tertiary referral centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578361" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21849166" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Neuroschistosomiasis: clinical symptoms and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488923" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Acute neuroschistosomiasis: two cases associated with cerebral vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21674195" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neuroschistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2875279" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Praziquantel in treatment of cerebral schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2115457" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Immunological involvement in the efficacy of praziquantel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10586908" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7677219" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548188" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Use of anthelminthic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251403" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Is praziquantel therapy safe during pregnancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701253" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Praziquantel for the treatment of schistosomiasis mansoni during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701253" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Praziquantel for the treatment of schistosomiasis mansoni during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26511959" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30370849" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The Mechanism of Action of Praziquantel: Six Hypotheses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17040833" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Chemotherapy of schistosomiasis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8531670" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Immuno-epidemiology of Schistosoma mansoni infections in a recently exposed community in Senegal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11703840" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16474094" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16113896" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403323" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742435" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20412175" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : High rate of failure in treatment of imported schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18345010" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Identification of oxadiazoles as new drug leads for the control of schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24955523" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Schistosomiasis control: praziquantel forever?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32810153" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1841998" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Activity of the artemether in experimental schistosomiasis mansoni.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33922522" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32966290" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25033291" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26921676" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34033646" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Associations between infection intensity categories and morbidity prevalence in school-age children are much stronger for Schistosoma haematobium than for S. mansoni.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27988094" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Human schistosomiasis in the post mass drug administration era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17674306" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17308729" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9444005" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Impact mass chemotherapy with praziquantel on schistosomiasis control in Fanhu village, People's Republic of China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9790428" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A mass chemotherapy trial of praziquantel on Schistosoma haematobium endemicity in Upper Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25059523" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mass drug administration with praziquantel reduces the prevalence of Schistosoma mansoni and improves liver morbidity in untreated preschool children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996452" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Imported strongyloidosis: a longitudinal analysis of 31 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34519344" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27470241" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35594896" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31881138" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Schistosomiasis - Assessing Progress toward the 2020 and 2025 Global Goals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129526" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A strategy to control transmission of Schistosoma japonicum in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25070942" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Can mass drug administration lead to the sustainable control of schistosomiasis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30813615" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Asian Schistosomiasis: Current Status and Prospects for Control Leading to Elimination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9467732" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : From discovery to eradication of schistosomiasis in Japan: 1847-1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790382" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15259480" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Schistosomiasis prophylaxis in vivo using N,N-diethyl-m-toluamide (DEET).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931751" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Waterborne infectious diseases--could they be consigned to history?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32076812" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Schistosomiasis-from immunopathology to vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35216369" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7551254" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Synthetic peptide vaccines for schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29905805" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Establishing the Production of Male Schistosoma mansoni Cercariae for a Controlled Human Infection Model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16783371" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27036511" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Advancing a vaccine to prevent human schistosomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27716365" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Schistosomiasis vaccines: where do we stand?
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
